9th Tumor Models San Francisco Summit 2025

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic.

Reuniting 180+ Preclinical, Translational, Discovery, Pharmacology, and Biology experts to share case studies in improving target selection, facilitating biomarker discovery, and achieving clinical translatability, the 9th Tumor Models San Francisco Summit is the definitive industry forum uniting the West Coast ecosystem of pharma and biotech to collaboratively advance the frontier of oncology research to the clinic.Dates: December 10-12, 2024.

5 Must-Attend Case Studies in 2025:

• Interrogate the translational relevance of humanized mouse models and investigate data indicating translational relevance to optimize selection criteria with Amgen
• Navigate ADC activity in immunocompetent models across syngenic and humanized models to assess clinical relevance and optimize dosing with AstraZeneca
• Evaluate T cell engagers with additional functionality and selection rationale for humanized mouse models including PBMCs, transgenic and tox models with Zymeworks
• Optimize decision making in outsourcing or developing internal capabilities for translational studies through cost-benefit models across multiple modalities with AstraZeneca
• Explore combination dosing strategies in bispecifics and CAR-T therapies and evaluate toxicity in mouse models to optimize targeted cytokine therapies with Regeneron